


| Health Canada Approves New Indication for ERLEADA®* (apalutamide) for the Treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) |
|
In the Phase 3 TITAN study, ERLEADA ® in combination with androgen deprivation therapy, achieved statistical significance in dual primary endpoints of overall survival and radiographic progression-free survival in patients with mCSPC regardless of extent of disease. TORONTO , Dec.
Posted: 2019-12-16 14:03:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.